Through tailored products, adaptable service and packaging choices, and unwavering support, Alpha Lifetech Inc. guarantees that researchers have access to the most fitting and efficient tools tailored to their research endeavors.
Our team of experienced scientists works closely with customers to design and execute tailored strategies for nanobody discovery, ensuring the generation of high-quality leads that align with project goals.
Antibody humanization from a broad range of parental species including mouse, rat, rabbit, llama, and avian.
Our Membrane Proteomics platform offers a comprehensive solution for the identification, quantification, and characterization of membrane proteins, providing valuable insights into their functions and interactions within the cell.
Alpha Lifetech can offer the native antibody libraries (scFv, Fab, VHH Formats and customized) from host animals like Goat, Camel and Llama.
Alpha Lifetech Inc. was founded by a group of scientists with extensive experience in membrane protein production, nanobody discovery, monoclonal development, and other pharmaceutical pre-development services. Based on our several technology service platforms, Alpha Lifetech Inc. has launched nearly 10,000 high-quality spot membrane protein reagents, cytokines, drug target antibodies and other related reagents. Whether you're working in the fields of immunology, cell biology, molecular biology, or any other scientific discipline, Alpha Lifetech's comprehensive range of research products will help you achieve accurate and reliable results. We pride ourselves on being able to offer a comprehensive set of high-quality products and services tailored to customer needs, which help advance the projects of scientific research institutions, academics, and enterprises in the life science industry.
A transformative strategy converting camelid-derived VHH single-domain antibodies into human-compatible therapeutics.
Nanobodies — the smallest functional antibody fragments derived from camelid heavy-chain-only antibodies — possess extraordinary properties: exceptional stability, small size (~15 kDa), deep tissue penetration, and the ability to bind cryptic epitopes inaccessible to conventional antibodies. However, their camelid origin raises immunogenicity concerns for human therapeutic applications. Nanobody humanization systematically replaces non-human framework residues with their human germline equivalents, minimizing immune recognition while preserving or even enhancing antigen-binding affinity. Modern humanization pipelines combine CDR grafting, back-mutation analysis, in silico immunogenicity prediction (using tools like EpiMatrix and NetMHCpan), and experimental affinity validation to deliver optimized humanized VHH candidates ready for IND-enabling studies.
Complementarity-determining regions from camelid VHH are grafted onto the closest human germline frameworks (IGHV families), followed by strategic back-mutations to restore structural integrity and binding potency.
Advanced computational tools screen humanized sequences for T-cell epitopes, HLA-binding peptides, and aggregation-prone motifs — dramatically reducing the risk of adverse immune responses in clinical settings.
Following humanization, candidates undergo rigorous SPR, BLI, and cell-based assays to confirm affinity, selectivity, and functional activity — ensuring therapeutic-grade performance before advancing to development.
The global nanobody therapeutics market is accelerating — driven by regulatory milestones, Big Pharma partnerships, and expanding clinical pipelines.
The nanobody therapeutics market was valued at over USD 500 million in 2023 and is projected to exceed USD 3.5 billion by 2032, growing at a CAGR of ~24%. The approval of caplacizumab (Cablivi®) by the FDA and EMA as the world's first nanobody-based drug has catalyzed massive investment and pipeline expansion across oncology, autoimmune diseases, and infectious disease indications.
Major pharmaceutical companies including Sanofi, AbbVie, Merck, and Boehringer Ingelheim have established strategic collaborations with nanobody-focused biotechs. These deals — often valued at hundreds of millions in milestone payments — validate the commercial potential of humanized nanobody platforms for next-generation biologic drugs.
As of 2024, over 40 nanobody-based therapeutics are in active clinical trials globally. Humanization is now a mandatory step for IND filing, with regulatory agencies (FDA, EMA) requiring robust immunogenicity risk assessments. Companies with validated humanization platforms hold significant competitive advantages in securing approvals and licensing deals.
The convergence of deep learning (AlphaFold2, RoseTTAFold) with antibody engineering has revolutionized humanization workflows. AI models now predict optimal back-mutation combinations, forecast immunogenicity profiles, and suggest novel humanized scaffold designs — compressing timelines from months to weeks and dramatically improving success rates.
Humanized nanobodies are redefining the boundaries of what biologics can achieve across multiple therapeutic modalities.
Humanized VHH antibodies can penetrate dense tumor stroma and bind GPCR targets, ion channels, and enzyme active sites inaccessible to conventional mAbs. They are engineered as bispecific constructs engaging CD3/CD28 T-cell co-stimulatory pathways, and as CAR-T cell receptor components — offering superior tumor infiltration and reduced off-target toxicity.
The exceptional stability of humanized nanobodies under aerosolization conditions makes them uniquely suited for inhaled therapeutics targeting RSV, influenza, SARS-CoV-2, and asthma-related cytokines (IL-4, IL-13, IL-33). Their small size enables efficient lung epithelial penetration and extended mucosal residence time.
Humanized nanobodies targeting transferrin receptor (TfR1) and LRP1 are being engineered as BBB-shuttle platforms, enabling delivery of therapeutic payloads to the CNS for Alzheimer's, Parkinson's, and brain tumor indications — a capability beyond conventional antibodies due to size constraints.
Humanized VHH domains serve as modular building blocks for bispecific, trispecific, and even hexavalent antibody constructs. Their small size minimizes steric hindrance in multi-domain formats. Fusion with albumin-binding nanobodies extends serum half-life to >7 days without Fc-mediated effector functions, ideal for anti-inflammatory indications.
Humanized nanobodies offer site-specific conjugation handles (engineered cysteines, non-natural amino acids) for highly homogeneous ADC production with defined drug-antibody ratios. Their rapid tumor internalization kinetics and low immunogenicity profile make them next-generation ADC warhead delivery vehicles for solid tumors.
Humanized pan-coronavirus nanobodies targeting conserved RBD epitopes demonstrate potent neutralization across SARS-CoV-2 variants, MERS-CoV, and bat coronaviruses. Their low-cost bacterial production and thermostability at ambient temperatures enable rapid deployment in resource-limited settings — a critical advantage for pandemic response.
Alpha Lifetech Inc. is committed to providing the highest level of customer services, competitive pricing, speedy delivery, and a comprehensive, cutting-edge product offering. Our sales and technical support staff are available to help you select the right products and service solutions. As a reliable supplier and partner, Alpha Lifetech Inc. always puts customers first. We cherish every opportunity to collaborate with worldwide customers in scientific exploration. Welcome to contact our technical support at any time.
Alpha Lifetech Inc. provides a wide range of technology platforms, including membrane protein, antibody discovery, single B cell sorting, and hybridoma technology. Whether you're engaged in immunology, cell biology, molecular biology, or any other scientific discipline, our comprehensive suite of services is designed to empower you with precise and dependable results. In the dynamic landscape of scientific research, access to dependable and top-tier tools is paramount for obtaining consistent and accurate outcomes.
Our years of manufacturing experience and refined products provide you with better protection
Comprehensive end-to-end platforms powering every stage of nanobody humanization and therapeutics discovery.
Our platform utilizes phage and yeast display technology to develop different forms of antibodies: VHH single domain antibodies, Fab antibodies, and scFv antibodies, resulting in high affinity and high specificity antibodies.
READ MORE
VHH Antibody Discovery Service
View Details
Fab Antibody Discovery Service
View Details
ScFv Antibody Discovery Service
View Details
Phage Display System
View Details
Phage Library Construction Service
View Details
The aptamer platform provided by Alpha Lifetech includes two categories: aptamer synthesis platform, which mainly involves SELEX aptamer library synthesis service and aptamer development service, and aptamer screening platform including screening services based on SELEX technology for proteins, peptides, cells, small molecules, and other target molecules, as well as aptamer optimization and identification analysis services.
READ MORE
Aptamer Synthesis Platform
View Details
Aptamer Screening Platform
View Details
Aptamer Optimization Service
View Details
Aptamer Analysis Service
View Details
Aptamer Research Service
View Details
Our monoclonal antibody development services include three technologies: phage display technology, single-B cell technology, and hybridoma cell technology, which produce monoclonal antibodies for different species.
READ MORE
Single B Cell Sorting Platform
View Details
Hybridoma Technology Platform
View Details
Phage Display Technology Platform
View Details
Mouse mAb Development Service
View Details
Rabbit mAb Development Service
View Details
We also provide a series of technical services related to antibody engineering, stable cell line construction, yeast display, protein interaction analysis, etc., laying the foundation for antibody development.
READ MORE
Stable Cell Line Construction Service
View Details
Animal Immunization Platform
View Details
Protein Interaction Service
View Details
Yeast Display Library Construction Service
View Details
Yeast Display Library Screening Service
View DetailsExceptional Nanobody discovery capabilities from Alpha Lifetech. Their team's dedication to customer satisfaction and scientific excellence is evident in every interaction. Grateful for their partnership and looking forward to future collaborations!
Quality products! Our experience with Alpha Lifetech has been nothing short of outstanding.
Reliable, responsive, and results-driven — Alpha Lifetech.
Simply put, Alpha Lifetech delivers. Their dedication to customer satisfaction and quality service is unmatched, and we're grateful to have them as a trusted partner.
Explore our complete range of services supporting every stage of humanized nanobody therapeutics discovery.
VHH Antibody Discovery Service
View Details
Fab Antibody Discovery Service
View Details
ScFv Antibody Discovery Service
View Details
Phage Display System
View Details
Single B Cell Sorting Platform
View Details
Hybridoma Technology Platform
View Details
Phage Display Technology Platform
View Details
Stable Cell Line Construction Service
View Details